07/01/2016 - Research led by prof. Peter Carmeliet and dr. Annelies Quaegebeur (VIB/KU Leuven) indicates that inhibition of PHD1 offers protection against stroke, via an unexpected mechanism, raising hope for future stroke treatment.
30/07/2015 - Scientists at VIB and KU Leuven have shown that reducing the expression of the PHD2 oxygen sensor impairs the ability of breast cancers to metastasize (spread) to other parts of the body.
22/07/2015 - With the appointment of seven barons, three baronesses, three knights and an earl, King Philip has raised fourteen people into peerage.
10/07/2015 - Sandra Schoors, Ulrike Bruning, Sarah-Maria Fendt and Peter Carmeliet (VIB Vesalius Research Center, KU Leuven) have discovered, contrary to all expectations, that fatty acid breakdown is essential for the proliferation of endothelial cells.
01/07/2015 - From September 8 – 10, 2015 VIB will host the interdisciplinary meeting on “Metabolism in Cancer and Stromal Cells” in Leuven.
26/06/2015 - Oncurious NV, an oncology company focused on the development of innovative medicines for the treatment of pediatric tumors, today announces the appointment of Prof. Dr Peter Carmeliet as its Chief Scientific Strategy Advisor.
01/04/2015 - Peter Carmeliet and Sarah-Maria Fendt (VIB/ KU Leuven) have discovered a new strategy to counteract blood vessel formation, based on their research which indicates that fatty acid breakdown is essential in the creation of new blood vessels.
18/11/2014 - On Tuesday November 18, Peter Carmeliet (VIB Vesalius Research Center, KU Leuven) took his audience on an exploration of the world of blood vessels.
06/11/2014 - Peter Carmeliet's research has a significant impact, this has been confirmed by an international study who has placed Peter Carmeliet amongst the global top 400 most influential scientists in biomedical research.
11/08/2014 - A study by investigators at VIB and KU Leuven has demonstrated that chloroquine also normalizes the abnormal blood vessels in tumors. This blood vessel normalization results in an increased barrier function and in enhanced tumor perfusion.
09/07/2014 - New therapeutic avenues for diabetes, inflammatory conditions & cancer.
12/12/2013 - New research reveals a new strategy to block blood vessel growth in various pathological conditions by depriving them of energy and building blocks necessary for growth.
01/08/2013 - New blood vessel formation (angiogenesis) stimulates the growth of cancer and other diseases. Anti-angiogenic inhibitors slow down cancer growth by disrupting the blood supply to the tumor.
28/02/2013 - Peter Carmeliet and his team (VIB-KU Leuven) joined forces with scientists at Massachusetts General Hospital in Harvard to study the role of the placental growth factor (PIGF) in the growth of this brain tumor.
06/07/2012 - VIB has teamed up with Cell for a symposium about angiogenesis, metabolic regulation and cancer biology, on July 6-8 2012 in Leuven, Belgium. Registration is now open.
24/05/2012 - AXA strongly expanded its support to scientific research on the global risks on the environment, human health and societies. In Belgium 1 million euro goes to Peter Carmeliet (VIB/KU Leuven).
19/10/2011 - In a study published in Nature, researchers identify a new role for Vascular Endothelial Growth Factor (VEGF) in regulating skin cancer stem cells.
14/06/2011 - Researchers at the VIB Vesalius Research Centre, K.U. Leuven, under the direction of Peter Carmeliet, have investigated the role of placental growth factor (PlGF) in mice with CML
03/02/2011 - The Fournier-Majoie Foundation for Innovation (FFMI) has awarded Max Mazzone of VIB-K.U.Leuven a grant for research into a new method of early detection of colon cancer.
18/11/2010 - VIB researchers Peter Carmeliet and Bart De Strooper have both been awarded Advanced Grants from the European Research Council. ERC Advanced Grants are the most prestigious European research grants, spanning a period of 5 years.
01/07/2010 - Oxford BioMedica and VIB-K.U.Leuven announce an award by the UK MND Association of a research grant to support the further development for the treatment of ALS with gene therapy.
28/06/2010 - Two of the five FWO prizes of EUR 100,000 were awarded to VIB scientists, namely Dirk Inzé (VIB-UGent) and Peter Carmeliet (VIB-K.U.Leuven).
10/02/2010 - The European Medicines Agency (EMEA) has recognized a Leuven lab’s candidate medicine to combat the neurodegenerative disease ALS (Amyotrophic Lateral Sclerosis) as a 'weesgeneesmiddel' (‘orphan medicine’).
08/01/2010 - His pioneering research on heart and vascular diseases and thrombosis has earned Peter Carmeliet the prestigious Ernst Jung Medical Award, one of the highest European prizes for biomedical research.
12/02/2009 - Our blood vessels have a built-in rescue-mechanism that springs into action when there is insufficient oxygen in our tissues. VIB scientists at K.U.Leuven have now discovered that this mechanism can be mobilized in the battle against cancer.
01/12/2008 - Permission has been granted to start the first safety and tolerability trial on patients for a remedy for ALS. ALS is an incurable, paralyzing neurodegenerative disorder that strikes 5 persons in every 100,000.
29/10/2007 - VIB scientists connected to the Katholieke Universiteit Leuven, in collaboration with the Flemish biotech company ThromboGenics, have been studying the anti-cancer action of anti-PLGF.
28/11/2004 - Research shows that rats with a severe form of ALS live longer following the administration of the VEGF protein as a remedy. These results open up new possibilities for the use of VEGF in the treatment of ALS.
28/10/2004 - VIB researchers have shown that new blood vessels do not grow in random directions, but that they are guided by specific signal molecules. This is a major step in the development of new targeted forms of therapeutic angiogenesis.
19/08/2004 - Belgian researchers from VIB (the Flanders Interuniversity Institute for Biotechnology), lead by Prof. Peter Carmeliet (K.U.Leuven) already indicated the importance of the VEGF growth factor in this illness.
26/05/2004 - Researchers from VIB (the Flanders Interuniversity Institute for Biotechnology), lead by Prof. Peter Carmeliet (K.U.Leuven) already indicated the importance of the VEGF protein in this illness, on the basis of genetic studies.